CLDN18 and neoplasm: XNW27011, with a homogenous DAR of 8, showed a favorable safety profile in the dose escalation cohort of solid tumor patients (Yu J. et al., 2024) and ORRs of 31% (9/29), 61% (19/31) and 67% (12/18) in dose expansion cohorts of 2.4, 3.0 and 3.6 mg/kg doses, respectively, of G/GEJAC patients with CLDN18.2 staining of 2+/3+ intensity in at least 5% of tumor cells (Yu et al., 2025a) in a phase I/II clinical trial (NCT06792435).